The Clinical Value of PET with Amino Acid Tracers for Gliomas WHO Grade II
Figure 4
MET PET from disease onset (a) to disease progression (d) of a patient with LGGs in the left hemisphere, showing a shift of weak hot-spot activity located in the left frontotemporal region (a, b), towards a stronger and more centrally located hot spot (c, d) during progressive disease. This patient received radiotherapy between the second (b) and third (c) PET investigation. MET PET was performed at approximately 12 months intervals from the time point of disease onset.
